NCT03287336View on ClinicalTrials.gov

Prevention of Postpartum Hemorrhage With Tranexamic Acid

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

September 1, 2023

Study Completion Date

September 30, 2023

Conditions
Postpartum Hemorrhage
Interventions
DRUG

Tranexamic Acid

Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.

Trial Locations (1)

20037

James Slota, Washington D.C.

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

George Washington University

OTHER

NCT03287336 - Prevention of Postpartum Hemorrhage With Tranexamic Acid | Biotech Hunter | Biotech Hunter